September 22, 2020

Perrigo has voluntarily recalled all unexpired albuterol sulfate inhalation aerosol manufactured by Catalent Pharma Solutions for Perrigo. The recall is due to possible clogging of the inhaler, which can result in patients not receiving enough or any medication.

Albuterol inhalers are used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Albuterol is often used as a rescue medication during emergency situations, which could expose patients to serious health risks if an inhaler becomes clogged during use. The FDA advises patients to:

  • immediately seek emergency care if needed;
  • use the Perrigo inhaler they have on hand, as needed and as directed by a doctor;
  • have extra inhalers or an alternative treatment available in case of malfunction, as some of the recalled inhalers stop working after several uses; and
  • contact their healthcare professional or pharmacist with questions.

In addition, the FDA reminds healthcare professionals and patients that albuterol inhalers are available through multiple manufacturers.

Perrigo has received several thousand complaints regarding its albuterol inhalers, primarily of clogging and failure to dispense sufficient medication. Catalent stopped producing and distributing the product on August 21, 2020, and is investigating the malfunction. The FDA asks healthcare professionals and patients to report unexpected side effects or quality problems associated with albuterol inhalers to its MedWatch program.

Additional information can be found on the FDA’s website.

Although the recall does not currently extend to the patient level, Benecard Central Fill will facilitate replacement in coordination with the manufacturer if a member reports issues with their Perrigo albuterol sulfate inhaler.

September 23, 2020

Updated Black Box Warning for Benzodiazepines

Read More
September 23, 2020

Sun Pharmaceuticals Voluntarily Recalls One Lot of Riomet ER

Read More
September 22, 2020

Perrigo Voluntarily Recalls Albuterol Inhalers

Read More
September 17, 2020

FDA Withdraws Approval for Belviq and Belviq XR

Read More